Coenzyme I for Injection: Subjects receive 7 consecutive days of intravenous infusion of Coenzyme I for injection.
NaCl (placebo): Subjects receive 7 consecutive days of intravenous infusion of NaCl(0.9%).
Study summary
Emerging evidence identifies vascular aging independently predicting cardiovascular events, yet effective clinical interventions remain lacking. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor whose levels decline with age, and preclinical studies suggest that boosting NAD+ can improve vascular function and structure. Preliminary clinical studies in healthy older adults indicate that supplementation with NAD+ precursors, such as nicotinamide riboside(NR) or nicotinamide mononucleotide (NMN), can reduce arterial stiffness as measured by pulse wave velocity (PWV). However, whether NAD+ supplementation can improve vascular endothelial function and exert anti-stiffening effects in patients who have already developed measurable arterial stiffness remains unknown. Based on this evidence, the investigator hypothesize that the Coenzyme I for Injection will reverse vascular aging in older adults with established arterial stiffening.
Eligibility
Sex
ALL
Min age
40 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
1. Ages 40-70 years;
2. cf-PWV was abnormally elevated and above the upper limit of its age-and blood-pressure matched reference range;
3. Systolic Blood Pressure \< 160 mmHg and ≥ 140 mmHg or Diastolic BP \< 100 mmHg ≥ 90mmHg;
4. Signed informed consent.
Exclusion Criteria:
1. Consumption of foods or medications containing high levels of NAD+, NR, NAM, NMN, or niacin-related components (including Vitamin B3 and natural health products) within 3 months prior to screening；
2. History of major cardiovascular or cerebrovascular events, including myocardial infarction, angina, stroke, or hospitalization for arterial revascularization；
3. Systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg；
4. Diagnosis of malignant tumor；
5. Known allergy or history of severe adverse reactions to Coenzyme I injection or any of its components；
6. History of severe allergies or infusion reactions；
7. Women who are pregnant, breastfeeding, or planning pregnancy；
8. Severe hepatic or renal dysfunction: ALT or AST \> 5 times the upper limit of normal; glomerular filtration rate ≤ 30 mL/min/1.73 m²；
9. Concurrent participation in another clinical trial without completion of the follow-up period；
10. Other conditions deemed by the investigator as unsuitable for inclusion, such as psychiatric or psychological disorders.
Primary outcome measure(s)
The change in flow-mediated vasodilation(FMD) — Day 8/28 Changes in FMD from baseline to day 8/28.
Trial sites (1)
Facility
City
Region
Status
Shanghai Tenth People's Hospital
Shanghai
Shanghai Municipality
More Shanghai 10th People's Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.